美国制酸剂市场规模、份额和趋势分析报告，按类型、最终用途、主要企业、竞争分析和细分预测，2025-2030 年

美国制酸剂市场摘要

美国制酸剂市场预计在 2024 年价值 30 亿美元，预计到 2030 年将达到 37.3 亿美元，2025 年至 2030 年的复合年增长率为 3.7%。饮食习惯的改变是预测期内推动市场成长的关键因素。

胃食道逆流症 (GERD)、消化性溃疡以及其他导致胃酸过多、消化不良和胃灼热等消化器官系统疾病的病例不断增加，预计也将推动市场扩张。根据美国疾病管制与预防中心 (CDC) 2024 年 12 月发布的报告，约有 5.9% 的美国成年人被诊断出患有溃疡。其他关键驱动因素包括人们对非处方 (OTC)制酸剂的认识不断提高以及其供应量不断增加，这些药物可以快速有效地缓解症状。

此外，压力、吸烟、饮酒、不良饮食和肥胖等生活习惯会导致酸相关症状，预计将进一步影响美国制酸剂产业的发展。例如，美国疾病管制与预防中心 (CDC) 于 2024 年 9 月发布的一份报告发现，2021 年 8 月至 2023 年 8 月期间，美国成年人的肥胖盛行率为 40.3%，其中 40-59 岁年龄层和教育程度较低的人口盛行率最高。重度肥胖影响 9.4% 的成年人，且在所有年龄层中，女性的盛行率均高于男性。

大多数产品开发都集中在咀嚼锭、液体、即溶片、品牌等给药形式。预计适度创新将来自组合配方和非处方益生菌混合配方，这些配方有望推动美国制酸剂行业的需求。

美国制酸剂市场受到严格监管，尤其因为制酸剂属于非处方药 (OTC)。 FDA 会监控其配方、标籤和市场宣传，以确保其安全性和有效性。新配方和组合药物必须符合特定的 OTC 专论标准，而某些成分（例如雷尼替丁）已因安全问题被撤回。这意味着製造商必须不断适应不断变化的监管准则，尤其是在产品安全、召回和透明度方面。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国制酸剂市场变数、趋势与范围

• 市场体系展望
  • 母市场展望
  • 相关/附随市场展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 美国制酸剂市场分析工具
  • 产业分析-波特五力分析
  • PESTEL分析
• 美国制酸剂市场：通路分析

第四章美国制酸剂市场：类型估计和趋势分析

• 类型细分仪表板
• 美国制酸剂市场：类型变化分析
• 美国制酸剂市场规模及趋势分析（2018-2030）
• 锭剂
• 液体
• 其他的

第五章美国制酸剂市场：最终用途估计与趋势分析

• 最终用途细分仪表板
• 美国制酸剂市场：最终用途差异分析
• 美国制酸剂市场规模及最终用途趋势分析（2018-2030）
• 医院药房
• 零售药局
• 其他的

第六章 竞争态势

• 主要市场参与企业的近期趋势和影响分析
• 公司/竞争对手分类
• 供应商格局
  • Key company heat map analysis, 2024
• 公司简介
  • Haleon Group of Companies.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Dr. Reddy's Laboratories Ltd.
  • Sanofi
  • Reckitt Benckiser Group plc
  • Sun Pharmaceuticals Ltd.
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Procter &Gamble

U.S. Antacids Market Summary

The U.S. antacids market size was estimated at USD 3.00 billion in 2024 and is projected to reach USD 3.73 billion in 2030, growing at a CAGR of 3.7% from 2025 to 2030. Changing dietary habits is a key factor propelling market growth over the forecast period.

Rising cases of digestive issues such as gastroesophageal reflux disease (GERD), peptic ulcers, and other stomach problems that cause acidity, indigestion, and heartburn are also expected to support market expansion. According to a report published by the CDC in December 2024, approximately 5.9% U.S. adults were diagnosed with ulcers. Other key drivers include rising awareness and easy access to over-the-counter (OTC) antacids, which provide fast and effective relief from symptoms.

In addition, lifestyle factors such as stress, smoking, alcohol use, poor diet, and obesity, all of which contribute to acid-related conditions, are expected to further influence the growth of the U.S. antacid industry. For instance, according to a report by the CDC published in September 2024, the prevalence of obesity was 40.3% among adults in the U.S. from August 2021 to August 2023. The highest rates are seen in adults aged 40-59 and those with lower education levels. Severe obesity affected 9.4% of adults, with women showing higher rates than men across all age groups.

Most product development focuses on delivery formats such as chewable, liquids, fast-dissolve tablets, and branding. Some moderate innovation comes from combo formulations or OTC-probiotic hybrids which are expected to drive the demand for U.S. antacid industry.

The U.S. antacid market is subject to the high impact of regulations, particularly because antacids are available over-the-counter (OTC). The FDA monitors formulation, labeling, and marketing claims to ensure safety and efficacy. New formulations or combinations must meet specific OTC monograph standards, and some ingredients, such as ranitidine, have been withdrawn due to safety concerns. This means manufacturers must continuously adapt to evolving regulatory guidelines, especially around product safety, recalls, and transparency.

U.S. Antacids Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the U.S. antacid market on the basis of types, and end-use:

• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Tablet
• Liquid
• Others
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospital Pharmacy
• Retail Pharmacy
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. End use
  • 1.2.3. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. End use outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Antacid Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Antacid Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. U.S. Antacid Market: Pipeline Analysis

Chapter 4. U.S. Antacid Market: Type Estimates & Trend Analysis

• 4.1. Type Segment Dashboard
• 4.2. U.S. Antacid Market: Type Movement Analysis
• 4.3. U.S. Antacid Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Tablet
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Liquid
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Others
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Antacid Market: End use Estimates & Trend Analysis

• 5.1. End use Segment Dashboard
• 5.2. U.S. Antacid Market: End use Movement Analysis
• 5.3. U.S. Antacid Market Size & Trend Analysis, by End use, 2018 to 2030 (USD Million)
• 5.4. Hospital Pharmacy
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Retail Pharmacy
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Company/Competition Categorization
• 6.3. Vendor Landscape
  • 6.3.1. Key company heat map analysis, 2024
• 6.4. Company Profiles
  • 6.4.1. Haleon Group of Companies.
    • 6.4.1.1. Company overview
    • 6.4.1.2. Financial performance
    • 6.4.1.3. Type benchmarking
    • 6.4.1.4. Strategic initiatives
  • 6.4.2. Bayer AG
    • 6.4.2.1. Company overview
    • 6.4.2.2. Financial performance
    • 6.4.2.3. Type benchmarking
    • 6.4.2.4. Strategic initiatives
  • 6.4.3. Boehringer Ingelheim International GmbH
    • 6.4.3.1. Company overview
    • 6.4.3.2. Financial performance
    • 6.4.3.3. Type benchmarking
    • 6.4.3.4. Strategic initiatives
  • 6.4.4. Dr. Reddy's Laboratories Ltd.
    • 6.4.4.1. Company overview
    • 6.4.4.2. Financial performance
    • 6.4.4.3. Type benchmarking
    • 6.4.4.4. Strategic initiatives
  • 6.4.5. Sanofi
    • 6.4.5.1. Company overview
    • 6.4.5.2. Financial performance
    • 6.4.5.3. Type benchmarking
    • 6.4.5.4. Strategic initiatives
  • 6.4.6. Reckitt Benckiser Group plc
    • 6.4.6.1. Company overview
    • 6.4.6.2. Financial performance
    • 6.4.6.3. Type benchmarking
    • 6.4.6.4. Strategic initiatives
  • 6.4.7. Sun Pharmaceuticals Ltd.
    • 6.4.7.1. Company overview
    • 6.4.7.2. Financial performance
    • 6.4.7.3. Type benchmarking
    • 6.4.7.4. Strategic initiatives
  • 6.4.8. Takeda Pharmaceutical Company Limited
    • 6.4.8.1. Company overview
    • 6.4.8.2. Financial performance
    • 6.4.8.3. Type benchmarking
    • 6.4.8.4. Strategic initiatives
  • 6.4.9. Pfizer Inc.
    • 6.4.9.1. Company overview
    • 6.4.9.2. Financial performance
    • 6.4.9.3. Type benchmarking
    • 6.4.9.4. Strategic initiatives
  • 6.4.10. Procter & Gamble
    • 6.4.10.1. Company overview
    • 6.4.10.2. Financial performance
    • 6.4.10.3. Type benchmarking
    • 6.4.10.4. Strategic initiatives

List of Tables

• Table 1 List of abbreviations
• Table 2 U.S. antacid market, by type, 2018 - 2030 (USD Million)
• Table 3 U.S. antacid market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. antacid market: market outlook
• Fig. 10 U.S. antacid competitive insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 Penetration and growth prospect mapping
• Fig. 14 Industry value chain analysis
• Fig. 15 U.S. antacid market driver impact
• Fig. 16 U.S. antacid market restraint impact
• Fig. 17 U.S. antacid market strategic initiatives analysis
• Fig. 18 U.S. antacid market: Type movement analysis
• Fig. 19 U.S. antacid market: Type outlook and key takeaways
• Fig. 20 Tablet market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Liquid market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 U.S. antacid Market: End use movement Analysis
• Fig. 24 U.S. antacid market: End use outlook and key takeaways
• Fig. 25 Hospital pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Retail pharmacy market estimates and forecasts,2018 - 2030 (USD Million)
• Fig. 27 Others market estimates and forecasts,2018 - 2030 (USD Million)